GSK signs gene therapy pact
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline reaffirmed its ambitions to build a rare diseases franchise by establishing a strategic alliance with the San Raffaele Telethon Institute for Gene Therapy, a joint venture between Fondazione Telethon and Fondazione San Raffaele, to research and develop gene therapeutic approaches using stem cells derived from patients' bone marrow. In line with the strategy exclusively revealed in Scrip last week (scripintelligence.com, 13 October 2010), GSK has secured an exclusive licence from the Italian institute to develop and commercialise a gene therapy for rare diseases.